JW Pharmaceutical’s ‘Emicizumab’ designated as orphan drug treating hemophilia A

Published: 2018-03-23 16:26:00
Updated: 2018-03-23 14:20:13

‘Emicizumab,’ a hemophilia A treatment which has been widely known to become a global new drug, has also raised attention of patients as being designated as an orphan drug even in Korea.

JW Pharmaceutical announced on the 21st that ‘Emicizumab,’ a hemophilia A treatment which secured an exclusiv...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean




Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.